Phase 1Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Sponsor
I-Mab Biopharma US Limited (Industry)
Enrollment
330 planned
Conditions
Solid Tumor; Advanced Cancer; Metastatic Cancer; Gastric Cancer; Gastroesophageal Junction Carcinoma; Esophageal Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC)
Interventions
TJ033721 (givastomig); TJ033721 (givastomig) , nivolumab, chemotherapy; TJ033721 (givastomig), chemotherapy; TJ033721 (givastomig), durvalumab, chemotherapy
Ages
adults, older adults
Registry
NCT04900818

Full record on ClinicalTrials.gov

From the registry

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

Primary outcomes

  • Dose-limiting toxicities (DLTs)
  • Incidence and severity of AEs
  • Maximum tolerated or administered dose (MTD, MAD)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered

In the news